Cart
sales@molnova.com
OXFBD04
CAS No. 2231747-03-6
OXFBD04( —— )
Catalog No. M26352 CAS No. 2231747-03-6
OXFBD04 is a potent and selective inhibitor of BRD4(IC50 of 166 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 122 | In Stock |
|
| 2MG | 67 | In Stock |
|
| 5MG | 111 | In Stock |
|
| 10MG | 181 | In Stock |
|
| 25MG | 339 | In Stock |
|
| 50MG | 494 | In Stock |
|
| 100MG | 670 | In Stock |
|
| 200MG | 923 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOXFBD04
-
NoteResearch use only, not for human use.
-
Brief DescriptionOXFBD04 is a potent and selective inhibitor of BRD4(IC50 of 166 nM).
-
DescriptionOXFBD04 is a potent and selective inhibitor of BRD4(IC50 of 166 nM).(In Vitro):OXFBD04 (0.01-100 μM) inhibits the cell growth of cancer cell lines. In MCF7 breast cancer cells, OXFBD04 (10 μM) induces MYC suppression.(In Vivo):OXFBD04 has optimized physicochemical properties (LE = 0.43; LLE = 5.74; SFI = 5.96), and greater metabolic stability (t1/2 = 388 min, CLint = 3.57 μL/min/mg).
-
In VitroOXFBD04 (0.01-100 μM; 48 hours) inhibits cancer cell lines growth. OXFBD04 (10?μM; for 10, 24, or 48?hours) induces MYC suppression in MCF7 breast cancer cells. Cell Viability AssayCell Line:A498 (renal), HT-29 (colon), and MCF7 (breast) cancer cell lines Concentration:0.01, 0.1, 1, 10, 100 μM Incubation Time:48 hoursResult:Inhibited cancer cell lines growth.
-
In VivoOXFBD04 has optimised physicochemical properties (LE=0.43; LLE=5.74; SFI=5.96), and good metabolic stability (t1/2=388?min). OXFBD04 has CLint of 3.57 μL/min/mg.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorAnti-infection| Antibacterial| Antibiotic| α-glucosidase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2231747-03-6
-
Formula Weight296.326
-
Molecular FormulaC17H16N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 250 mg/mL (843.68 mM)
-
SMILESCc1noc(C)c1-c1cc(O)cc(c1)C(O)c1cccnc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nishida M, Murakawa T, Kamimura T, Okada N, Sakamoto H, Fukada S, Nakamoto S, Yokota Y, Miki K. In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative. Antimicrob Agents Chemother. 1976 Jul;10(1):1-13.
molnova catalog
related products
-
CBP/EP300-IN-1
CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
-
GSK046
GSK046 is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins(IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively).
-
PBRM1-BD2-IN-8
PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor with PBRM1-BD2 Kd of 4.4 μM, PBRM1-BD2 IC50 of 0.16 μM, and PBRM1-BD5 Kd of 25 μM; PBRM1-BD2-IN-8 shows anti-cancer activity.
